study, where in ATF7IP::JAK2 mediated acute lymphoblastic leukemia (ALL), CHZ-868 is potent against the ruxolitinib resistant variants such as Y931C and L983F (45). The gene discussed is JAK2; the disease is acute lymphoblastic leukemia.